CN1922158A - 异硫脲衍生物 - Google Patents

异硫脲衍生物 Download PDF

Info

Publication number
CN1922158A
CN1922158A CNA2005800060942A CN200580006094A CN1922158A CN 1922158 A CN1922158 A CN 1922158A CN A2005800060942 A CNA2005800060942 A CN A2005800060942A CN 200580006094 A CN200580006094 A CN 200580006094A CN 1922158 A CN1922158 A CN 1922158A
Authority
CN
China
Prior art keywords
compound
formula
alkyl
aryl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800060942A
Other languages
English (en)
Chinese (zh)
Inventor
F·格利克曼
M·施特赖夫
G·托马
H-G·策尔韦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1922158A publication Critical patent/CN1922158A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005800060942A 2004-02-27 2005-02-25 异硫脲衍生物 Pending CN1922158A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0404434.3 2004-02-27
GBGB0404434.3A GB0404434D0 (en) 2004-02-27 2004-02-27 Organic compounds

Publications (1)

Publication Number Publication Date
CN1922158A true CN1922158A (zh) 2007-02-28

Family

ID=32051024

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800060942A Pending CN1922158A (zh) 2004-02-27 2005-02-25 异硫脲衍生物

Country Status (10)

Country Link
US (1) US7671078B2 (https=)
EP (1) EP1720845A1 (https=)
JP (1) JP2007523941A (https=)
KR (1) KR20060124722A (https=)
CN (1) CN1922158A (https=)
AU (1) AU2005219531B2 (https=)
CA (1) CA2556386A1 (https=)
GB (1) GB0404434D0 (https=)
RU (1) RU2376297C2 (https=)
WO (1) WO2005085219A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101917848B (zh) * 2007-11-06 2014-02-12 巴坎-法尔玛有限责任公司 用于治疗子宫收缩过强病症的s-烷基异硫脲衍生物
CN115996741A (zh) * 2020-03-11 2023-04-21 百欧林纳克斯有限公司 用于治疗急性呼吸窘迫综合征及病毒感染的cxcr4抑制剂
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022385A2 (en) * 2005-08-18 2007-02-22 Novartis Ag Use of cxcr4 binding molecules for the treatment of whim syndrome
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
CN102088856B (zh) 2008-07-09 2015-11-25 巴斯夫欧洲公司 包含异*唑啉化合物的杀虫活性混合物i
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
WO2012061662A1 (en) * 2010-11-03 2012-05-10 Glycomimetics, Inc. Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors
PT2794626T (pt) 2011-12-22 2018-01-12 Glycomimetics Inc Compostos de antagonistas de e-selectina
RU2503450C1 (ru) * 2012-04-19 2014-01-10 Федеральное Государственное Бюджетное Учреждение "Медицинский Радиологический Научный Центр" Министерства Здравоохранения и Социального Развития Российской Федерации (ФГБУ МРНЦ Минздравсоцразвития России) Противоопухолевое средство
CA2891514C (en) 2012-12-07 2020-08-25 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
ES2754549T3 (es) 2014-12-03 2020-04-20 Glycomimetics Inc Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
EP3497131B1 (en) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
WO2019108750A1 (en) 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CN111566117A (zh) 2017-12-29 2020-08-21 糖模拟物有限公司 E-选择蛋白和半乳凝素-3的异双功能抑制剂
WO2019173229A1 (en) 2018-03-05 2019-09-12 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
MX2023003409A (es) * 2020-09-28 2023-06-26 Ermium Therapeutics Derivados de isotiourea ciclica como moduladores de cxcr4.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3542802A (en) * 1968-07-03 1970-11-24 Searle & Co 3-(n - benzylthiocarbamoylthiomethyl)-6,7-dihydro - 5h - imidazo(2,1-b)thiazolium chloride and congeners
BE758145A (fr) * 1969-10-29 1971-04-28 Smith Kline French Lab Iso-thio-urees et derives
BE758146A (fr) * 1969-10-29 1971-04-28 Smith Kline French Lab Derives de l'amidine
IL49528A (en) 1975-05-21 1980-11-30 Smith Kline French Lab Imidazolyl(or thiazolyl)methylthio(or butyl)guanidine or thiourea derivatives,their preparation and pharmaceutical compositions comprising them
US4041167A (en) * 1976-01-19 1977-08-09 Diamond Shamrock Corporation Antiinflammatory imidazothiazoles
IE47458B1 (en) * 1977-11-07 1984-03-21 Leo Pharm Prod Ltd Quinolylguanidine derivatives
CA1131226A (en) * 1978-09-28 1982-09-07 Tomohiko Munakata Heterocyclic compounds
JPS57169490A (en) * 1981-04-10 1982-10-19 Kumiai Chem Ind Co Ltd 2,3-disubstituted-5,6-dihydro-imidazo(2,1-b)thiazole, its salt and their preparation
CA1271480A (en) * 1985-04-22 1990-07-10 Toyo Jozo Co., Ltd. 5,6-dihydroimidazo[2,1-b]thiazole-2-carboxamide derivatives or salts thereof
ATE308515T1 (de) 1999-02-05 2005-11-15 Oridigm Corp Antizymmodulatoren sowie deren verwendung
AU2001290243A1 (en) * 2000-09-20 2002-04-02 Nikken Chemicals Co., Ltd. Novel thiazole bicyclic compounds
EP1368355B1 (de) * 2001-03-14 2006-06-07 Grünenthal GmbH Substituierte pyrazolo- und thiazolopyrimidine als analgetika

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101917848B (zh) * 2007-11-06 2014-02-12 巴坎-法尔玛有限责任公司 用于治疗子宫收缩过强病症的s-烷基异硫脲衍生物
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
CN115996741A (zh) * 2020-03-11 2023-04-21 百欧林纳克斯有限公司 用于治疗急性呼吸窘迫综合征及病毒感染的cxcr4抑制剂

Also Published As

Publication number Publication date
GB0404434D0 (en) 2004-03-31
RU2006134019A (ru) 2008-04-10
US20070161618A1 (en) 2007-07-12
CA2556386A1 (en) 2005-09-15
US7671078B2 (en) 2010-03-02
WO2005085219A1 (en) 2005-09-15
JP2007523941A (ja) 2007-08-23
KR20060124722A (ko) 2006-12-05
AU2005219531B2 (en) 2009-01-15
RU2376297C2 (ru) 2009-12-20
AU2005219531A1 (en) 2005-09-15
EP1720845A1 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
CN1922158A (zh) 异硫脲衍生物
CN100351251C (zh) 吲哚基马来酰亚胺衍生物
KR100583704B1 (ko) 4-아미노-5-페닐-7-시클로부틸-피롤로 (2,3-ｄ) 피리미딘유도체
JP4362377B2 (ja) ２，４−ジアミノピリミジン誘導体
CN101568544B (zh) 包含4‑[9‑(四氢‑呋喃‑3‑基)‑8‑(2,4,6‑三氟‑苯氨基)‑9h‑嘌呤‑2‑基氨基]‑环己烷‑1‑醇的固体形式，其组合物，及其用途
CN1083448C (zh) 1-苯基-4-苄基哌嗪化合物多巴胺受体亚型的特异性配体(d4)
CN1144587C (zh) 副作用减轻剂
CN100413867C (zh) 4-氨基-5-苯基-7-环己基-吡咯并[2,3-d]嘧啶衍生物
CN1852900A (zh) 可用于治疗增殖性病症的2,4－二(苯基氨基)嘧啶类
TWI454476B (zh) 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
CN1839130A (zh) N－取代的吡唑基－酰胺基－苯并咪唑基的c－kit抑制剂
CN105481862B (zh) Flt3激酶的新型抑制剂及其用途
CN1918158A (zh) 作为蛋白激酶抑制剂的化合物和组合物
US20080234294A1 (en) Cxcr4 Binding Molecules
US20090149469A1 (en) Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
CN1742005A (zh) 吲哚基马来酰亚胺衍生物
CN1842529A (zh) 用作蛋白激酶抑制剂的化合物和组合物
JP2015516462A (ja) 単環式ヘテロアリールシクロアルキルジアミン誘導体
WO2016115869A1 (zh) Flt3激酶的新型抑制剂及其用途
WO2020223306A1 (en) Pim kinase inhibitor compositions and uses thereof
US20090247548A1 (en) Pyrrolopyrimidine derivatives for treating proliferative diseases
MXPA06009696A (en) Isothiourea derivatives
US11045449B2 (en) 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070228